Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com
Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

April 9th 2025

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

MS wordcloud | Image Credit: © arloo-stock.adobe.com
5 Ongoing Clinical Trials Evaluating Treatment for MS

March 14th 2025

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

March 12th 2025

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com
Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

January 8th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
July 2nd 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
July 2nd 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
July 2nd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 2nd 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
July 2nd 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
July 2nd 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
July 2nd 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
July 2nd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

The Mediterranean diet largely consists of higher fruit, vegetable, legume, and fish intake. | image credit: sonyakamoz - stock.adobe.com
June 19th 2024

Mediterranean Diet May Reduce Risk of Multiple Sclerosis

Kyle Munz
A prospective cohort study, using data from the UK Biobank, suggested that the Mediterranean diet could provide benefits to patients with multiple sclerosis.
Gray matter is an abundant brain tissue found in the cerebellum, brain stem, and cerebrum | image credit: iushakovsky - stock.adobe.com
June 13th 2024

Gray Matter Atrophy in MS a Strong Indicator of Progression, Study Suggests

Kyle Munz
A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive disease.
Myelin sheath damage in MS concept | image credit: Artur - stock.adobe.com
June 7th 2024

Aerobic Exercise Could Benefit MS Management, Further Research Needed

Kyle Munz
A small cohort demonstrated the potential benefits aerobic exercise regimens hold for managing fatigue symptoms in multiple sclerosis (MS), but more studies are needed.
Eye imaging | Image credit: Richman Photo - stock.adobe.com
May 31st 2024

Retinal Vasculature Pathology Linked With MS Disease Burden

Rose McNulty
Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS.
Cannabis Leaves and Stethoscope | image credit: New Africa - stock.adobe.com
May 30th 2024

Cannabis Treatment Showcases Promising Benefits for Managing Adverse Symptoms of MS

Kyle Munz
A real-world study assessed the impact of cannabis-based medicinal products on health-related quality of life in patients with multiple sclerosis (MS).
Man Wrestling With Sleeplessness | image credit: mtrlin - stock.adobe.com
May 16th 2024

Sleep Quality in MS Impacted by Comorbidities, Study Finds

Kyle Munz
This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
RRMS AI-Concept | image credit: Evadne - stock.adobe.com
May 8th 2024

Serum Neurofilament Light Changes Not Always Apparent in Active RRMS, Study Finds

Kyle Munz
A prospective study found evidence of serum neurofilament light (sNfL) level increases in patients affected by active forms of relapsing-remitting multiple sclerosis (RRMS); however, these findings were not significant enough to suggest sNfL measurements replace clinical or MRI monitoring of disease activity.
Resistance Band Exercise Demonstration | image credit: Maridav - stock.adobe.com
May 2nd 2024

Resistance Training Shows Promise for Improving Muscle Strength in MS

Kyle Munz
A recent meta-analysis that assessed prescribed exercise in managing multiple sclerosis (MS) detailed the benefits of resistance training for improving muscle weakness in this patient population.
Clinician Taking Notes on Clinical Trial Concept | image credit: toeytoey - stock.adobe.come
April 26th 2024

Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS

Kyle Munz Brooke McCormick
Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Social Diversity, Representation Concept | image credit: undrey - stock.adobe.com
April 24th 2024

Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds

Kyle Munz Brooke McCormick
Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Dr Ari Green on Promising Remyelination Therapies and Patient Outcomes in MS
April 12th 2024

Dr Ari Green on Promising Remyelination Therapies and Patient Outcomes in MS

Kyle Munz Brooke McCormick
Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.
dr mitzi joi williams
April 9th 2024

Dr Mitzi Joi Williams Discusses Clinical Trial Accessibility Challenges, Solutions

Brooke McCormick
Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.
dr krystyn van vliet
April 7th 2024

Dr Krystyn Van Vliet on Tackling Scalability, Cost When Using 3D Platforms for MS Drug Discovery

Brooke McCormick
Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.
Patrick Vermersch, MD, PhD
March 28th 2024

The Promise of Frexalimab in MS: Part 3

Kyle Munz
Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.
Neurologic Disease MS Concept | image credit: ralwel - stock.adobe.com
March 19th 2024

Distinguishing Biomarkers Identified in MS Outcomes

Kyle Munz
Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
dr krystyn van vliet
March 15th 2024

Dr Krystyn Van Vliet on Using Engineered 3D Platforms to Identify Potential MS Drug Candidates

Brooke McCormick
Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.
FDA on Paper Texture | Image credit: Araki Illustrations - stock.adobe.com
March 11th 2024

FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Forms of MS

Kyle Munz
The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
Patrick Vermersch, MD, PhD
March 7th 2024

The Promise of Frexalimab in MS: Part 2

Kyle Munz
Patrick Vermersch, MD, PhD, University of Lille, France discusses the next steps in frexalimab trials and the findings that have surprised him the most thus far, the second part of an interview.
dr xavier montalban
March 6th 2024

Dr Xavier Montalban Discusses Phase 3 evolutionRMS Trial Designs, Outcomes

Brooke McCormick
While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).
ateyeh soroush
March 4th 2024

Study Uses NIRS to Assess Hypoxia-Related Brain Function Impairment in Patients With MS

Brooke McCormick
Ateyeh Soroush, a PhD candidate at the University of Calgary, explains her ongoing study utilizing near-infrared spectroscopy (NIRS) to investigate hypoxia-related brain function impairment in patients with multiple sclerosis (MS).
Patrick Vermersch, MD, PhD
February 26th 2024

The Promise of Frexalimab in MS Treatment: Part 1

Kyle Munz
Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.
Vitamin D Molecule Concept | image credit: Katsiaryna Hatsak - stock.adobe.com
February 19th 2024

Vitamin D Pathway Associated With MS Susceptibility

Kyle Munz
A meta-analysis of 3 case-controlled MS studies showed an association between susceptibility to multiple sclerosis (MS) and the vitamin D pathway.
Stem Cell Concept | image credit: Anusorn - stock.adobe.com
February 12th 2024

Hematopoietic Stem Cell Transplantation Shown to Benefit MS Prognoses

Kyle Munz
A national single-center observational retrospective study reveals the long-term benefits of hematopoietic stem cell transplantation in the treatment of multiple sclerosis (MS).
3D Concept Choroid Plexus | Image credit: mybox - stock.adobe.com
February 9th 2024

Choroid Plexus Indicated in MS Pathology

Kyle Munz
A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
MRI Brain Scan for MS Lesions Model | image credit: yossarian6 - stock.adobe.com
February 5th 2024

Ibudilast Shows Promise for Reducing Lesion Volume in Progressive MS

Kyle Munz
The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients.
Black and White Pregnancy Portrait | image credit: Gajus - stock.adobe.com
February 1st 2024

Further Studies Required as MS DMT Exposure During Pregnancy Increases

Kyle Munz
A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.
Student Raising Hand in University Classroom | image credit: THANANIT - stock.adobe.com
January 24th 2024

DMT Uptake in MS Potentially Linked to Education Level, Study Suggests

Kyle Munz
A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS).
Stigma Spelled in Blocks | image credit: MP Studio - stock.adobe.com
January 17th 2024

Multiple Factors Affect Stigma Perceptions in MS

Kyle Munz
A cross-sectional analysis evaluated a myriad of socioeconomic and demographic factors that drive stigma experienced by patients with multiple sclerosis (MS).
Pregnant Woman Pondering Cigarettes | image credit: NDABCREATIVITY - stock.adobe.com
January 15th 2024

Prenatal Exposure to Tobacco Smoke May Increase MS Risk

Kyle Munz
Exposure to tobacco smoke in utero has the potential to make offspring more vulnerable to developing multiple sclerosis (MS).
3D Mitochondria | image credit: crevis - stock.adobe.com
January 11th 2024

Mitochondrial Dysfunction Linked to MS, Further Studies Needed on Metabolic Impact

Kyle Munz
More research is necessary to understand cerebral oxygen consumption as a predictive biomarker for brain atrophy in multiple sclerosis (MS); however, this study found that mitochondrial dysfunction could have a role in the underlying pathophysiology of MS.
<12345678
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo